Evotec OAI in discovery agreement with Nuvios

Published: 19-May-2004

Evotec OAI has entered into a collaboration with Nuvios, of Cambridge, Massachusetts, for the screening of novel small molecule compounds for potential new drugs for the treatment and prevention of osteoporosis.


Evotec OAI has entered into a collaboration with Nuvios, of Cambridge, Massachusetts, for the screening of novel small molecule compounds for potential new drugs for the treatment and prevention of osteoporosis.

Evotec OAI will apply its ultra high-throughput screening (uHTS), including proprietary, confocal fluorescence, as well as other technologies for the rapid identification of biologically active compounds to Nuvios's proprietary assays for profiling the effects of compounds on osteoclast and osteoblast growth and differentiation. The objective of the collaboration is to discover novel activators of bone anabolic activity.

'The collaboration with Nuvios leverages recent breakthroughs in the understanding of the biology and chemistry around anabolic bone formation,' said Joern Aldag, president and ceo of Evotec OAI. 'We are delighted to work with Nuvios in this exciting area, and we look forward to applying our skills in assay development and high-throughput screening to help create novel drugs for osteoporosis.'

  

You may also like